Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Moodys
Dow
Citi
Baxter
Fish and Richardson
Colorcon
Express Scripts
Farmers Insurance

Generated: October 22, 2017

DrugPatentWatch Database Preview

LIALDA Drug Profile

« Back to Dashboard

What is the patent landscape for Lialda, and what generic Lialda alternatives are available?

Lialda is a drug marketed by Shire and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in seventeen countries.

The generic ingredient in LIALDA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

Summary for Tradename: LIALDA

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list123
Clinical Trials: see list9
Patent Applications: see list5,070
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LIALDA at DailyMed

Pharmacology for Tradename: LIALDA

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire
LIALDA
mesalamine
TABLET, DELAYED RELEASE;ORAL022000-001Jan 16, 2007ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LIALDA

Drugname Dosage Strength RLD Submissiondate
mesalamineDelayed-release Tablets1.2 gLialda12/16/2009

International Patent Family for Tradename: LIALDA

Country Document Number Estimated Expiration
Canada2377299► Subscribe
China1720919► Subscribe
ItalyMI991316► Subscribe
Russian Federation2245148► Subscribe
European Patent Office1198226► Subscribe
Turkey200200561► Subscribe
Japan2003501458► Subscribe
Germany60001835► Subscribe
Denmark1198226► Subscribe
Austria324104► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
UBS
Farmers Insurance
Novartis
Baxter
Julphar
Boehringer Ingelheim
AstraZeneca
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot